Cytokines have shown great potential in tumor immunotherapy. Although only a few drugs have been approved, many cytokine drugs developed based on next-generation cytokine drug development strategies have entered clinical trials and achieved the expected results. Based on a well-established cell therapy and immuno-oncology platform, Creative Biolabs has developed a series of cytokine-related activity alteration strategies.

Cytokine/Chemokine

Cytokines are regulators secreted by a variety of cells and involved in cellular communication, mainly including interleukin, interferon (IFN), some members of the tumor necrosis factor (TNF) superfamily, chemokines, and growth factors. Interleukins play an important role in activating and regulating innate and innate immune responses influenced by white blood cells. IFN has a range of other immunostimulatory and inhibitory functions, as well as antitumor activity and autoimmune effects. The TNF superfamily has pro-inflammatory or anti-inflammatory activity. Chemokines are composed of at least 47 structurally relevant cytokines that typically have the ability to stimulate cell migration, interact with the extracellular matrix (ECM), and thus control directed cell migration.

Fig.1 Chemokine ligands and receptors.¹

Cytokine/Chemokine-based Strategies for Immunotherapy Development

Cytokines exhibit pleiotropy because they mediate more than one action, often acting on more than one cell type, as well as overlapping, i.e., two or more cytokines induce similar effects. Therefore, these two properties need to be taken into account when developing cytokine-based cancer immunotherapies. Creative Biolabs offers different activity alteration strategies to safely and effectively modulate cytokine activity for cancer immunity.

Strategies to enhance cytokine activity

The administration of natural cytokines can be limited by factors such as short half-lives and toxicity in vivo. Creative Biolabs achieves enhanced cytokine activity through a variety of methods such as extended half-life, fusion of other proteins such as immunoglobulins, their Fc regions, or albumin, and more.

Strategies to inhibit cytokine activity

Our Service

• Immunostimulatory Cytokine-based Cancer Immunotherapy Development Service
  Cytokines affect the expression and function of other cytokines by activating specific signaling pathways. For example, IL-6 and IL-1β can jointly activate the STAT3 signaling pathway, upregulate the expression of IL-23, and further promote the expression of IL-17. This cross-activation of signaling pathways allows for a more rapid response and better results due to synergies between cytokines. Creative Biolabs provides cytokine-based cancer immunotherapy development services to enhance activity through various cytokine alteration strategies.
• Immunosuppressive Cytokine-based Cancer Immunotherapy Development Service
  IL-10, TGF-β, IL-4, and IL-35 predominate in the tumor setting of multiple cancers and are primarily responsible for immunosuppression. These cytokines can regulate the growth and proliferation of cancer cells, alter the epigenome and transcriptional network of naïve immune cells, and can also directly act on cytotoxic CD8⁺ T cells or natural killer (NK) cells, and inhibit their effector function and proliferation. Creative Biolabs offers cytokine-based cancer immunotherapy development services to inhibit cytokine activity through various cytokine alteration strategies.

Our Capabilities

Over the years, Creative Biolabs has developed an in-depth understanding of cytokine and cytokine receptor structure, receptor biology, and intracellular signaling mechanisms. With a focus on the new nature of cytokines and new engineering methods, you can trust us with your research project under the leadership of a team of professionals.

If you have any items of interest in the field of cancer immunotherapy of cytokines or have any questions, please do not hesitate to contact us for assistance. We provide you with technical support around the clock and respond quickly within a short time.

Reference

1. Vilgelm, Anna E, and Ann Richmond. "Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy." Frontiers in immunology. (2019) 10 333.

For Research Use Only | Not For Clinical Use